WuXi PharmaTech Schedules Second-Quarter 2015 Earnings Release

SHANGHAI, July 29, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, today announced that it will release financial results for the second-quarter of 2015 after the New York Stock Exchange closes on Thursday, August 13, 2015 (which will be Friday morning, August 14, 2015 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Friday, August 14, 2015, to discuss the second-quarter 2015 financial results and recent business activities. The conference call may be accessed by calling:

Mainland China	4001 200 539
Hong Kong	800 905 927
Singapore	800 616 3222
United Kingdom	0800 015 9725
United States	1855 298 3404
United States -- New York (toll)	[phone]
Other countries (toll)	[phone]
Conference ID	2278500

A telephone replay will be available two hours after the call's completion at:

Mainland China	4001 842 240
Hong Kong	800 966 697
Singapore	800 616 2127
United Kingdom	0800 169 7301
United States	1866 846 0868
Conference ID	2278500

A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com/.

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally.  The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.  For further information, please visit http://www.wuxiapptec.com.

For more information, please contact:

Ronald Aldridge
LaVoieHealthScience
[phone] x109
[e-mail] 
[e-mail]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wuxi-pharmatech-schedules-second-quarter-2015-earnings-release-300120802.html

SOURCE WuXi PharmaTech

Copyright 2015 PR Newswire